https://european-biotechnology.net/wp-content/uploads/2024/08/Biopole-SA-1030x373-1.jpg3731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-08-21 06:58:372024-08-21 06:58:37Vandria closes Series A round at CHF28.3m
https://european-biotechnology.net/wp-content/uploads/2024/08/BioNtechMedilink.png356765Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-08-19 11:58:592024-08-19 11:58:59BioNTech: ADC study continues with conditions
https://european-biotechnology.net/wp-content/uploads/2024/08/Bavarian-Nordic-production-site-in-kvistgaard.jpg317634Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-08-16 08:37:002024-08-16 08:37:00Bavarian Nordic A/S applies for EU label extension of mpox vaccine
